NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Seto Yoshihiro
To Hideto
Abstract
[Problem] The purpose of the present invention is to provide a prophylactic and/or ameliorating agent that is effective against peripheral neuropathy caused by a cancer chemotherapeutic agent. [Solution] Provided is a prophylactic and/or ameliorating agent that is for peripheral neuropathy caused by a cancer chemotherapeutic agent and that contains an iron compound as an active ingredient.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kudo Takashi
Akamine Shoshin
Kurosawa Nobuyuki
Isobe Masaharu
Abstract
The present invention pertains to: an anti-APLP1 monoclonal antibody of which the epitope is the amino acid sequence from no. 232 to no. 238 in SEQ ID NO. 1; and an anti-APLP1 monoclonal antibody in which CDR1, CDR2, and CDR3 in a light chain respectively have the amino acid sequences described in SEQ ID NO. 5, 7, and 9, and CDR1, CDR2, and CDR3 in a heavy chain respectively have the amino acid sequences described in SEQ ID NO. 12, 14, and 16. The present invention also pertains to: a method for recovering extracellular vesicles derived from brain neurons by using the anti-APLP1 monoclonal antibody of the present invention; methods for detecting a neuropsychiatric disease biomarker and for recovering neuron-derived components, the methods each comprising recovering extracellular vesicles by said method; and a test reagent and a test kit which are for use in recovering extracellular vesicles and which include the anti-APLP1 monoclonal antibody of the present invention. The present invention provides: an anti-APLP1 monoclonal antibody having a higher specificity with respect to NDE; a method for recovering extracellular vesicles by using said antibody; a method for detecting a neuropsychiatric disease biomarker using the recovered extracellular vesicles; a test drug; and a test kit.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Ono Hideki
Kato Kengo
Mizutani Shoya
Abstract
[Problem] The purpose of the present invention is to provide a method for reducing or removing Si in an aluminum alloy, and reducing or removing Fe and Cu components is also possible. [Solution] This method for reducing or removing Si contained in an aluminum alloy is characterized by comprising: a step for holding the temperature at a melting temperature at which the aluminum alloy and Sn are melted; a step for lowering the temperature from the melting temperature, and holding the temperature at a Si crystallization temperature at which the solid Si is crystallized while maintaining a molten state of Sn and Al, thereby separating the solid Si; and a step for further lowering the temperature and holding the temperature at an Al crystallization temperature at which Al is crystallized but Sn is in a molten state, thereby separating and recovering the solid Al.
ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO NUCLEOCAPSID PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 OR FRAGMENT THEREOF, AND USE OF SAID ANTIBODY OR SAID FRAGMENT
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kawahata, Takashi
Masuya, Takahiro
Yuhara, Kosuke
Nishimura, Kengo
Kitazawa, Hiroaki
Kuroita, Toshihiro
Isobe, Masaharu
Kurosawa, Nobuyuki
Abstract
Provided are an antibody or fragment thereof specifically bindable to the NTD or CTD of the N protein of SARS-CoV-2, and use of the antibody or fragment thereof. An antibody or fragment thereof specifically bindable to the amino acid sequence of SEQ ID NO: 1 or 2 is disclosed.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Uta Daisuke
Hashimoto Satoshi
Nakamura Hideki
Kunigami Toshihiro
Abstract
Provided is a pharmaceutical composition for treating or preventing peripheral neuropathy induced by a chemotherapeutic agent, the pharmaceutical composition containing an alkalinizing agent. Administration of this pharmaceutical composition enables the treatment or prevention of peripheral neuropathy induced by a chemotherapeutic agent, especially a chemotherapeutic agent for cancer. Also provided is an anticancer pharmaceutical composition containing an alkalinizing agent and a chemotherapeutic agent for cancer, by which the expression of peripheral neuropathy is suppressed. Administration of this pharmaceutical composition enables cancer treatment with suppressed expression of peripheral neuropathy.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Toyooka, Naoki
Okada, Takuya
Nishikawa, Hiroyuki
Abstract
The present invention provides a compound of formula (I):
The present invention provides a compound of formula (I):
wherein R1, R2, R3, R4, k, l, m and n are as defined in the specification,
or a pharmaceutically acceptable salt thereof with the effect of inhibiting T-type calcium channels and a medicament useful for the treatment of a disease associated with the activation of T-type calcium channels.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Motozono Chihiro
Ueno Takamasa
Goto Yoshihiko
Kishi Hiroyuki
Hamana Hiroshi
Abstract
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypeptide (P1), (P2) or (P3): (P1) a polypeptide comprising an amino acid sequence represented by SEQ ID NO: 1 (KAYNVTQAF); (P2) a polypeptide comprising an amino acid sequence obtained by deleting, inserting, substituting, or adding 1-6 amino acids in the amino acid sequence represented by SEQ ID NO: 1; and (P3) a polypeptide comprising an amino acid sequence having at least 80% identity to the amino acid sequence represented by SEQ ID NO: 1.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
10.
CATALYST, METHOD FOR MANUFACTURING SAME, AND METHOD FOR MANUFACTURING LIQUID FUEL
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Doi, Makoto
Hashimoto, Yukako
Urabe, Haruki
Iwasaki, Toshihiko
Tsubaki, Noritatsu
Guo, Xiaoyu
Abstract
The purpose of the present invention is to improve the yield of C5 or higher hydrocarbons that are manufactured using carbon monoxide and hydrogen as raw materials. The present invention provides a catalyst having a metal-based catalyst that contains a metal compound having activity in a Fischer-Tropsch synthesis reaction and that generates hydrocarbons from a synthesized gas, and a carrier catalyst that includes a zeolite carrying the metal-based catalyst, said catalyst enabling hydrocarbons to be manufactured from the synthesized gas, wherein the metal compound contains at least one type of metal selected from the group consisting of cobalt, manganese, and ruthenium, the amount of manganese carried being 1-3 wt%, the amount of Ru carried being 0.5-2 wt%, and the amount of Co carried being 10-30 wt%. The zeolite includes a porous zeolite that breaks down carbon chains in the generated hydrocarbons, the pores in the porous zeolite being mesopores having an opening diameter of 2-50 nm inclusive, and the ratio of silicon to aluminum in the zeolite being 2.5-3.5 inclusive.
C07C 1/04 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon monoxide with hydrogen
C07C 9/14 - Acyclic saturated hydrocarbons with five to fifteen carbon atoms
C07C 9/22 - Acyclic saturated hydrocarbons with more than fifteen carbon atoms
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japan)
Wook-Cheol Kim (Japan)
NATIONAL UNIVERISTY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Sadami Tsutsumi (Japan)
Inventor
Ishihara, Masakazu
Ueno, Yoshimitsu
Murata, Tomoaki
Otsuki, Yukito
Kobayashi, Yusuke
Oka, Yoshinobu
Kim, Wook-Cheol
Aida, Tetsuo
Tsutsumi, Sadami
Abstract
To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.
A61B 17/58 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tohda Chihiro
Shibue Shogo
Abstract
Provided is a pharmaceutical or food and beverage composition which is for prevention or treatment of an optic nerve disorder and which includes diosgenin or a diosgenin derivative as an active ingredient thereof.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Izuhara Kenji
Nunomura Satoshi
Nanri Yasuhiro
Kitajima Isao
Uta Daisuke
Abstract
Provided is a technique for preventing or treating a periostin-mediated disease and pruritus associated with the disease. The present invention relates to, for example, a prophylactic or therapeutic agent for a periostin-mediated disease or pruritus associated with the disease, said agent containing a specific periostin receptor antagonist as an active ingredient.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (Japan)
Inventor
Nakaji, Tadashi
Yamamoto, Shinpei
Abstract
The present invention relates to a random copolymer which has a constituent unit represented by formula (I) and a constituent unit represented by formula (II). (In formulae (I) and (II), each of R1and R3independently represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; R2represents an alkyl group having 1 to 6 carbon atoms; R4represents an alkylene group having 1 to 3 carbon atoms; R5 represents an alkyl group having 1 to 6 carbon atoms; n represents an integer of 1 to 15; and * represents a bonding hand for a bond with an adjacent constituent unit.)
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Sano, Yosuke
Kurimura, Hideki
Aoyama, Takuya
Yonamine, Wataru
Tsubaki, Noritatsu
Abstract
24222 through a steam reforming reaction and an aqueous gas shift reaction by supplying steam to a light saturated hydrocarbon gas and the second gas; and obtaining a liquid hydrocarbon by using the first gas and the third gas as materials.
C10G 2/00 - Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon
C01B 3/38 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts
C10G 1/10 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal from rubber or rubber waste
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
SAKURA SEIKI CO., LTD. (Japan)
Inventor
Kobashi Daisuke
Yoshida Toshiko
Okabe Motonori
Arai Kenichi
Arakawa Masahiko
Abstract
The present invention addresses the problem of effectively promoting granulation in a dermal defect or a subcutaneous tissue defect caused by a severe burn. To solve this problem, provided is a cell to be used for treating a burn, said cell being derived from the placenta of an animal, including humans, and promoting healing.
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kishimoto Tadamitsu
Metwally Hozaifa Saad Hassan
Ozawa Tatsuhiko
Abstract
The present invention provides: a sepsis and/or septic shock therapeutic agent containing, as an active ingredient, a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidate compound for an active ingredient of a sepsis and/or septic shock therapeutic agent including a step for selecting a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a colitis treatment agent containing, as an active ingredient, a compound that promotes phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidate compound for an active ingredient of a colitis treatment agent including a step for selecting a compound that promotes phosphorylation of threonine at position 749 of human STAT1; a systemic lupus erythematosus treatment agent containing, as an active ingredient, a compound that inhibits human STAT1; and a method for screening a candidate compound for an active ingredient of a systemic lupus erythematosus treatment agent including a step for selecting a compound that inhibits human STAT1.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Mizubayashi, Mai
Tomono, Naoki
Katayama, Yuka
Cao, Jingdi
Tsubaki, Noritatsu
Yang, Guohui
Abstract
A hydrocarbon synthesis catalyst is for reacting a raw material gas including hydrogen and carbon dioxide to convert to hydrocarbons, wherein when elemental analysis of a surface of the hydrocarbon synthesis catalyst to be brought into contact with the raw material gas is performed by energy dispersive X-ray spectroscopy (SEM-EDX), 15 to 65% by mass of Fe, 10 to 40% by mass of O, 0.04 to 30% by mass of Na, 0 to 15% by mass of Ni, and 5 to 30% by mass of Cr are detected.
B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen
National University Corporation University of Toyama (Japan)
SAKURA SEIKI CO., LTD. (Japan)
Inventor
Oba, Jiro
Yoshida, Toshiko
Okabe, Motonori
Soko, Chika
Arakawa, Masahiko
Abstract
A raw amniotic membrane placed in a processing tank (10) is continuously heated by a far-IR heater (14) provided in the processing tank (10). During a decompression operation in which the interior of the processing tank (10) is placed in a decompressed state, and a recompression operation in which the pressure in the decompressed interior of the processing tank (10) is raised slightly toward atmospheric pressure, the raw amniotic membrane is dried while the water molecules present therein are subjected to energy via microwave irradiation from a microwave irradiation device (30) provided in the processing tank (10). By repeating this multiple times, the amniotic membrane is dried while cells and tissue structures are maintained. The amniotic membrane can be used on a wound site as a coating material or scaffold material after removing a necrosis layer and the like from a severe burn wound patient to retain cytokines and physiologically active substances secreted from infiltrating cells and promote favorable granulation including neoangiogenesis and growth of fibroblasts. This enhances the probability of survival of the patient and therapeutic effect (without the risk of keloid formation).
National University Corporation University of Toyama (Japan)
Inventor
Yamamoto, Seiji
Sasahara, Masakiyo
Hamashima, Takeru
Okuno, Noriko
Abstract
A pharmaceutical composition for preventing or treating cystic lymphangioma comprising an agent that causes suppression of expression of amphiregulin, suppression of secretion of amphiregulin, and/or inhibition of binding of amphiregulin with an amphiregulin receptor, or an agent that causes suppression of expression of an amphiregulin receptor, suppression of activation of an amphiregulin receptor, and/or inhibition of binding of an amphiregulin receptor with amphiregulin, as an active ingredient.
National University Corporation University of Toyama (Japan)
SAKURA SEIKI CO., LTD. (Japan)
Inventor
Fujisaka, Michiro
Shojaku, Hideo
Ito, Shinsuke
Yoshida, Toshiko
Okabe, Motonori
Soko, Chika
Arakawa, Masahiko
Abstract
The present invention addresses the problem of providing a material as a scaffold used to prevent poor skin grafting when there is a defect in the perichondrium or periosteum or a defect in subcutaneous tissue. As a solution, there is provided a dry amniotic membrane manufactured according to a specific drying process. In more detail, a raw amniotic membrane placed in a processing tank (10) is continuously heated by a far-infrared heater (14) provided inside the processing tank (10), while performing a decompression operation where the interior of the processing tank (10) is placed in a decompressed state and irradiation of the raw amniotic membrane with microwaves from a microwave generating device (30) provided inside the processing tank (10) to apply energy to water molecules present inside the amniotic membrane and cause drying during a pressure recovery operation that slightly raises the pressure inside the depressurized processing tank (10) toward atmospheric pressure. By providing amniotic membrane, which has been dried by repeating the above process a plurality of times to retain its cellular and tissue structure, as a scaffold used to prevent poor skin grafting when there is a defect in the perichondrium or periosteum or a defect in the subcutaneous tissue, it is possible to enhance the healing effect of a skin graft.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Awale, Suresh
Toyooka, Naoki
Abstract
The present invention addresses the problem of providing a novel pharmaceutical composition, and in particular, a novel anti-cancer pharmaceutical composition, and a novel compound used in said pharmaceutical composition. The present invention provides a pharmaceutical composition containing, as an active component, the compound represented by formula (I), or a pharmacologically acceptable salt thereof.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
C07C 235/56 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 255/57 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
C07C 255/60 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Awale, Suresh
Toyooka, Naoki
Abstract
A purpose of the present invention is to provide a novel pharmaceutical composition, particularly a novel anti-cancer pharmaceutical composition, and a novel compound used for the anti-cancer agent. The present invention provides a pharmaceutical composition including, as an active ingredient, a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
KYOWA HAKKO BIO CO., LTD. (Japan)
Inventor
Miyamoto Aya
Ogino Fumiko
Koizumi Keiichi
Mori Hisashi
Abstract
The purpose of the present invention is to provide a glutaminase inhibitor effective for prophylaxis, amelioration or therapy of cancer, inflammatory disease, nervous system disease, aging and obesity. The present invention pertains to a glutaminase inhibitor comprising, as an active component, at least one substance selected from the group consisting of peptides, L-carnitine, N2-(1-oxopropyl)-L-glutamine, N2-(1-oxobutyl)-L-glutamine, sialic acid, eucomic acid and (4)-imidazoleacetic acid hydrochloride or a pharmaceutically acceptable salt thereof.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Yoshikane, Takafumi
Kurosawa, Nobuyuki
Isobe, Masaharu
Abstract
The invention provides an antibody that specifically binds to a 5′ to 3′ exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5′ to 3′ exonuclease activity of a DNA polymerase, or a fragment thereof.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Awale, Suresh
Toyooka, Naoki
Okada, Takuya
Abstract
The present invention pertains to a compound represented by formula (I) and having a new anti-cancer effect, or to a stereoisomer or tautomer of the compound, or pharmaceutically permissible salts thereof. The present invention sets forth a preparation method and use for the compound represented by formula (I), as well as a pharmaceutical composition containing said compound.
C07C 49/835 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Toyooka, Naoki
Okada, Takuya
Nishikawa, Hiroyuki
Abstract
The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically acceptable salt thereof, and a drug that is useful in the treatment of diseases caused by activation of T-type calcium channels.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Toyooka, Naoki
Okada, Takuya
Nishikawa, Hiroyuki
Abstract
The present invention provides a compound of formula (I) wherein R1, R2, R3, R4, k, l, m and n are as defined in the specification, or a pharmaceutically acceptable salt thereof with the effect of inhibiting T-type calcium channels and a medicament useful for the treatment of a disease associated with the activation of T-type calcium channels.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tobe, Kazuyuki
Ozawa, Tatsuhiko
Mori, Hisashi
Yoshida, Tomoyuki
Igarashi, Yoshiko
Abstract
The present invention addresses the problem of providing: an antibody which can bind to CD206 and can remove a CD206-positive M2 macrophage in an adipose tissue; an agent for killing a CD206-positive M2 macrophage cell; and a pharmaceutical composition for preventing or treating a metabolic disorder. The present invention provides: an antibody which can bind to CD206 and can remove a CD206-positive M2 macrophage in an adipose tissue; an agent for killing a CD206-positive M2 macrophage cell, the agent containing the antibody as an active ingredient; and a pharmaceutical composition for preventing or treating a metabolic disorder, the pharmaceutical composition containing the antibody as an active ingredient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tobe, Kazuyuki
Kado, Tomonobu
Ozawa, Tatsuhiko
Mori, Hisashi
Yoshida, Tomoyuki
Igarashi, Yoshiko
Abstract
The present invention addresses the problem of clarifying the relationship between the onset and progression of cancer and macrophages and providing a novel pharmaceutical composition for preventing or treating cancer. The present invention provides: a pharmaceutical composition for preventing or treating cancer, said pharmaceutical composition containing, as an active ingredient, a substances having an ability to kill CD206-positive M2 macrophages; an agent for killing fibroblasts around a tumor tissue; an agent for promoting the infiltration of cytotoxic T cells into a tumor tissue; an agent for inhibiting the expression of a gene, said gene inhibiting the infiltration of cytotoxic T cells into a tumor, in fibroblasts; an agent for promoting the proliferation of cytotoxic T cells; an agent for enhancing the cytotoxic activity of cytotoxic T cells; and an agent for enhancing the expression of a gene that relates to the cytotoxicity of cytotoxic T cells.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tohda Chihiro
Nagase Tsukasa
Abstract
Provided is an agent or composition that is useful in, inter alia, the prevention, treatment, and/or improvement of neurodegenerative disease. The agent or composition is configured to contain a component that suppresses the expression of hemopexin, or a component (A) that inhibits the activity of hemopexin.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
TOYAMA PREFECTURE (Japan)
Inventor
Morinaga, Yoshitomo
Yamamoto, Yoshihiro
Kawasuji, Hitoshi
Tani, Hideki
Abstract
Provided is a method for evaluating virus-neutralizing antibodies using dried blood adhering to filter paper, the method including: a step for mixing a blood sample obtained by extracting the dried blood adhering to the filter paper and a pseudotype virus, which coats the coat protein of a target virus and in the genes of which a reporter gene is incorporated, to obtain a mixture; a step for infecting a susceptible cultured cell line with the psuedotype virus in the mixture; and a step for detecting the presence or measuring the amount of pseudotype-virus-neutralizing antibodies in the blood sample on the basis of the expression level of the reporter gene after infection.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
TOYAMA PREFECTURE (Japan)
Inventor
Ozawa Tatsuhiko
Kishi Hiroyuki
Isobe Masaharu
Kurosawa Nobuyuki
Morinaga Yoshitomo
Yamamoto Yoshihiro
Niimi Hideki
Tani Hideki
Abstract
The present invention addresses the problem of providing a novel and effective antibody that binds to the spike protein of SARS-CoV-2, and in particular addresses the problem of providing an antibody that inhibits binding between SARS-CoV-2 and ACE2 or an antibody that inhibits the entry of SARS-CoV-2 into the cell. The present invention provides, for example, an antibody that has the following combination of complementarity-determining regions (CDRs) and that binds to the spike protein of SARS-CoV-2, or an antigen-binding fragment from said antibody: CDRH1, 2, and 3 and CDRL1, 2, and 3 composed of the amino acid sequences of SEQ ID NOS: 9, 10, 11, 20, 21, and 22.
INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (Japan)
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Izawa Seiichiro
Hiramoto Masahiro
Morimoto Masahiro
Naka Shigeki
Abstract
This organic electroluminescent element 10 comprises a plurality of organic semiconductor layers sandwiched between a pair of electrodes 3, 4. The organic semiconductor layers include: a first organic semiconductor layer 1 containing a first organic semiconductor material; and a second organic semiconductor layer 2 containing a second organic semiconductor material and a third organic semiconductor material. The first organic semiconductor layer and the second organic semiconductor layer form a joining surface, and the first organic semiconductor material and the second organic semiconductor material satisfy, inter alia, requirements regarding a prescribed energy level.
H05B 33/12 - Light sources with substantially two-dimensional radiating surfaces
H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japan)
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Ishihara, Masakazu
Ueno, Yoshimitsu
Murata, Tomoaki
Otsuki, Yukito
Kobayashi, Yusuke
Oka, Yoshinobu
Aida, Tetsuo
Abstract
The purpose of the present invention is to have biodegradable medical implement to dissolve in the living body at a suitable dissolution speed. This biodegradable medical implement is formed of a magnesium member. In this biodegradable medical equipment, a layer of magnesium crystal grains in which the (0001 face) in a hexagonal structure is aligned towards the obverse surface side is continuous around the entire periphery, in at least one cross-section.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Yoshikane, Takafumi
Kurosawa, Nobuyuki
Isobe, Masaharu
Abstract
Provided is an antibody capable of inhibiting the 5'→3' exonuclease activity of a DNA polymerase, or a fragment of the antibody. Disclosed is an antibody capable of binding specifically to a 5'→3' exonuclease activity domain of a DNA polymerase, or a fragment of the antibody.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Yamamoto, Seiji
Sasahara, Masakiyo
Hamashima, Takeru
Okuno, Noriko
Abstract
Provided is a pharmaceutical composition for preventing or treating cystic lymphangioma and containing, as an active ingredient, an agonist that inhibits expression of amphiregulin, inhibits secretion, and/or inhibits binding to amphiregulin receptors, or an agonist that inhibits expression of amphiregulin receptors, inhibits activation, and/or inhibits binding with amphiregulin.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
SAKURA SEIKI CO., LTD. (Japan)
Inventor
Oba Jiro
Yoshida Toshiko
Okabe Motonori
Soko Chika
Arakawa Masahiko
Abstract
A raw amniotic membrane placed in a processing tank (10) is continuously heated by a far-IR heater (14) provided in the processing tank (10). During a decompression operation in which the interior of the processing tank (10) is placed in a decompressed state, and a recompression operation in which the pressure in the decompressed interior of the processing tank (10) is raised slightly toward atmospheric pressure, the raw amniotic membrane is dried while the water molecules present therein are subjected to energy via microwave irradiation from a microwave irradiation device (30) provided in the processing tank (10). By repeating this multiple times, the amniotic membrane is dried while cells and tissue structures are maintained. The amniotic membrane can be used on a wound site as a coating material or scaffold material after removing a necrosis layer and the like from a severe burn wound patient to retain cytokines and physiologically active substances secreted from infiltrating cells and promote favorable granulation including neoangiogenesis and growth of fibroblasts. This enhances the probability of survival of the patient and therapeutic effect (without the risk of keloid formation).
A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
39.
SKIN GRAFT SUPPLEMENTING/CUSHIONING MEMBER FOR AURICLE SKIN DEFECT
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
SAKURA SEIKI CO., LTD. (Japan)
Inventor
Fujisaka Michiro
Shojaku Hideo
Ito Shinsuke
Yoshida Toshiko
Okabe Motonori
Soko Chika
Arakawa Masahiko
Abstract
The present invention addresses the problem of providing a material as a scaffold used for the purpose of preventing poor skin grafting when there is a defect in the perichondrium/periosteum or a defect in the subcutaneous tissue. As a solution, there is provided a dry amniotic membrane produced by a specific drying process. Specifically, a raw amniotic membrane placed in a processing tank (10) is continuously heated by a far-IR heater (14) provided in the processing tank (10). During a decompression operation in which the interior of the processing tank (10) is placed in a decompressed state, and a recompression operation in which the pressure in the decompressed interior of the processing tank (10) is raised slightly toward atmospheric pressure, the raw amniotic membrane is dried while the water molecules present therein are subjected to energy via microwave irradiation from a microwave generation device (30) provided in the processing tank (10) . The amniotic membrane, which is dried while repeating the above process a plurality of times to retain the cellular/tissue structure, is provided as a scaffold used for preventing skin graft anomalies when there is a defect in the perichondrium/periosteum or a defect in the subcutaneous tissue, thereby making it possible to enhance the healing effect of grafting.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
KAZUSA DNA RESEARCH INSTITUTE (Japan)
Inventor
Motoo, Iori
Ohara, Osamu
Kawashima, Yusuke
Abstract
A pancreatic cancer test method including measuring a protein in feces of a subject, wherein the protein is one or two selected from the group consisting of collagen α-1(I) chain, protein S100-A8, all-trans-retinol dehydrogenase, peroxiredoxin 4, cysteine-rich secretory protein 3, protein-glutamine γ-glutamyltransferase E, α-enolase, lactotransferrin, signal peptidase complex catalytic subunit 11A, plasminogen activator inhibitor 2, eukaryotic translation initiation factor 6, and malate dehydrogenase 1.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
41.
ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO NUCLEOCAPSID PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 OR FRAGMENT THEREOF, AND USE OF SAID ANTIBODY OR SAID FRAGMENT
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kawahata, Takashi
Masuya, Takahiro
Yuhara, Kosuke
Nishimura, Kengo
Kitazawa, Hiroaki
Kuroita, Toshihiro
Isobe, Masaharu
Kurosawa, Nobuyuki
Abstract
Provided are: an antibody capable of binding specifically to an NTD or a CTD of N-protein of SARS CoV2 or a fragment of the antibody; and a use of the antibody or the fragment. Disclosed is an antibody capable of binding specifically to the amino acid sequence represented by SEQ ID NO: 1 or 2, or a fragment of the antibody.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
SAKURA SEIKI CO., LTD. (Japan)
Inventor
Amano Kouji
Yoshida Toshiko
Okabe Motonori
Soko Chika
Arakawa Masahiko
Abstract
The present invention addresses the problem of providing a wound contact member (contact layer) that promotes direct wound healing when executing persistent negative pressure wound therapy (NPWT). As a solution to the problem, dry amnion is produced by a specific drying treatment, that is, raw amnion mounted in a treatment tank (10) is continuously heated by an infrared heater (14) provided inside the treatment tank (10), and during a depressurization operation in which a depressurized state occurs inside the treatment tank and a pressure restoration operation in which the pressure inside the treatment tank (10) in the depressurized state is slightly increased towards atmospheric pressure, this raw amnion is irradiated with microwaves from a microwave generating device (30) provided inside the treatment tank (10), and the raw amnion is dried while applying energy to water molecules present in the amnion. This process is repeated a plurality of times, and thereby the healing effect of negative pressure wound therapy (NPWT) can be increased when the amnion that is dried while holding a cell/tissue structure is used as a contact layer during execution of NPWT for the treatment of an open abdominal wound and/or wound dehiscence.
A61L 15/40 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof
A61L 27/00 - Materials for prostheses or for coating prostheses
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
KAGOSHIMA UNIVERSITY (Japan)
SHOWA UNIVERSITY (Japan)
Inventor
Takasaki Ichiro
Toyooka Naoki
Okada Takuya
Kurihara Takashi
Gouda Hiroaki
Abstract
The present invention pertains to: a compound represented by formula (I) (in the formula, R11-61-61-61-61-6-alkyl amino group, R21-61-61-61-61-6-alkyl amino group, R31-61-61-6-alkyl group, and R43-123-12-hydrocarbon group) or a salt thereof, or a solvate thereof; and an analgesic drug that contains the compound or a salt thereof, or a solvate thereof.
C07D 239/91 - Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
44.
BETAINE MONOMER, POLYMER, COMPOSITION CONTAINING SAID POLYMER, AND MOLDED OBJECT
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (Japan)
Inventor
Nakaji, Tadashi
Saruwatari, Yoshiyuki
Matsuoka, Kazuyoshi
Yamamoto, Shinpei
Abstract
The present invention relates to a betaine monomer which includes a positively charged moiety and a negatively charged moiety that are equivalent to each other, wherein the positively charged moiety and the negatively charged moiety are linked to each other by a branched alkylene group having 2-6 carbon atoms.
C08F 20/02 - Monocarboxylic acids having less than ten carbon atomsDerivatives thereof
C07C 309/14 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
C09D 133/00 - Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereofCoating compositions based on derivatives of such polymers
45.
ANTIDEPRESSANT/ANXIOLYTIC DRUG IN WHICH PAC1 RECEPTOR ANTAGONIST IS USED
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
OSAKA UNIVERSITY (Japan)
Inventor
Kurihara Takashi
Takasaki Ichiro
Hashimoto Hitoshi
Hayata Atsuko
Shintani Yusuke
Abstract
The present invention relates to an antidepressant/anxiolytic drug containing a compound represented by formula (I) or (II): (in the formulas, R11-61-62-61-61-61-6-haloalkoxy group, or an optionally substituted phenyl group; R21-61-62-61-61-61-6-haloalkoxy group, or an optionally substituted phenyl group; an R is an indazolyl group substituted by a halogen atom, an optionally substituted phenyl group, a pyrazolyl group, or an optionally substituted aralkyl group), or a salt thereof, or a solvate of these.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Fujisaka, Michirou
Shojaku, Hideo
Ono, Hidenori
Ono, Hideaki
Abstract
Provided is a tool for inspecting/treating benign paroxysmal positional vertigo, the tool enabling a user to recognize, in therapy pertaining to the physical position of the head, the positional relationship between a semicircular canal and an otolithic organ at each position of the head, the movement direction of an otolith, the position of the otolith, and nystagmus of a patient. A tool 2 for inspecting/treating benign paroxysmal positional vertigo, the tool 2 comprising an equilibrium function inspection device 4 mounted on the head of a patient, and a vestibular model 6 mounted on the equilibrium function inspection device 4. The vestibular model 6 includes three semicircular canals 20, and an otolithic organ 22 connected to the three semicircular canals 20, and moreover is formed from a transparent synthetic resin so as to be hollow. A liquid is sealed inside the vestibular model 6, and a plurality of otolithic models CP having a specific gravity higher than that of the liquid are accommodated therein so as to be capable of moving. Obstruction pieces 26a, 26b, 26c that allow passage of the liquid but obstruct passage of the otolithic models CP are positioned in enlarged sections 24a, 24b, 24c of the three semicircular canals 20.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
47.
Substrates coated with selective cell separation or cell culture polymers
C08G 61/04 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Niimi, Hideki
Kitajima, Isao
Miyakoshi, Akio
Higashi, Yoshitsugu
Abstract
A method for enabling rapid and accurate determination of the number of bacterial cells in a specimen using a PCR method includes the following steps: (1) a first PCR step of carrying out a PCR method using a nucleic acid derived from a specimen as a template and a universal primer pair for amplifying a bacterial 16S rRNA gene to obtain a first amplification product; (2) a second PCR step of carrying out a nested PCR method using a primer pair(s) for amplifying an internal sequence(s) of the sequence of the first amplification product obtained by the first PCR step to obtain a second amplification product; and (3) a bacterial number determination step of obtaining the number of bacterial cells in the specimen based on the amount of the second amplification product obtained in the second PCR step and using calibration data.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Nitta, Atsumi
Tokoro, Kazuki
Abstract
The present invention provides a nonhuman model animal for bipolar disorder, in which the expression of Teneurin-4 protein is reduced in the prefrontal cortex. The present invention also provides a method for creating a nonhuman model animal for bipolar disorder, the method including reducing the expression of Teneurin-4 protein in the prefrontal cortex.
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
C08F 220/60 - Amides containing nitrogen in addition to the carbonamido nitrogen
C08L 33/02 - Homopolymers or copolymers of acidsMetal or ammonium salts thereof
C08L 33/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
C08L 33/24 - Homopolymers or copolymers of amides or imides
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
National University Corporation University of Toyama (USA)
Inventor
Niimi, Hideki
Otsuki, Shinya
Kitajima, Isao
Abstract
The improved Tm mapping method using imperfect-match linear long quenching probes can accurately distinguish among and identify microorganisms at least at the genus level and often at the species level even in a real-time PCR instrument having measurement errors of Tm values between PCR tubes within ±0.5° C. Therefore, the Tm mapping method can be performed in almost all real-time PCR instruments and can identify unspecified infection-causing pathogenic microorganisms in about 4 hours after sample collection.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
KANAZAWA MEDICAL UNIVERSITY (Japan)
Inventor
Kondo Takashi
Abe Hitoshi
Kurachi Masayoshi
Suzuki Michio
Uehara Takashi
Abstract
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be used as an active ingredient of a drug for central nervous system diseases or as a candidate compound for a precursor of said active ingredient. In formula (1), R1, R2, and R3each independently represent a substance selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkoxy group having 1-6 carbon atoms, and at least one of R1, R2, and R3 is a hydroxy group.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Tsubota, Maho
Toyooka, Naoki
Nishikawa, Hiroyuki
Abstract
A new analgesic has been developed for T-type calcium channels as therapeutic targets.
The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1):
or a pharmaceutically acceptable salt or solvate thereof.
The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
GENERAL INCORPORATED ASSOCIATION MEDICAL INNOVATION CONSORTIUM (Japan)
Inventor
Hasegawa Hideyuki
Abstract
Provided is a feature which improves the spatial resolution and contrast of ultrasonic tomograms compared to methods based on correlation between echo signals. Provided is an ultrasonic tomogram generation method, the method including: an estimation step SA100 for receiving an ultrasonic echo generated by M (a natural number greater than or equal to 2) ultrasonic oscillators, estimating noise in M-channel echo signals output by ultrasonic probes which output echo signals, and calculating a weighting coefficient, that emphasizes echo from a reception focus point, in accordance with a signal-to-noise ratio in the M-channel echo signals; and a generation step SA110 for generating a beamformer, representing an ultrasonic tomogram, from the M-channel echo signals by using the weighting coefficient calculated in the estimation step SA100.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
57.
Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide
National University Corporation University of Toyama (Japan)
Inventor
Tohda, Chihiro
Kaku, Taiichi
Miyazaki, Hiroyuki
Abstract
A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
58.
METHOD FOR RAPID IDENTIFICATION OF CANDIDA IN WHICH INCOMPLETE MATCH PROBES ARE USED
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Higashi Yoshitsugu
Niimi Hideki
Kitajima Isao
Abstract
[Problem] To develop a method with which it is possible to rapidly identify Candida species that cause candidiasis, which is a type of fungal infection. [Solution] Eight Candida species can be identified by carrying out real time PCR using one universal primer set and three incomplete match probes, generating three Tm values, and comparing the values with data registered in a database. Therefore, this method is useful as a method for the rapid identification of Candida species in candidiasis.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
59.
THUJOPSIS DOLABRATA AND INHALATION FORMULATION THEREOF
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kimura, Tomoatsu
Seki, Shoji
Makino, Hiroto
Abstract
Provided is an idiopathic scoliosis marker that, in a test for biological fluid such as blood, urine, and saliva, and spinal fluid, enables accurate, early detection of an onset of idiopathic scoliosis and prompt, reliable prediction of the condition, and that is capable of serving as a diagnostic or therapeutic marker. This idiopathic scoliosis marker comprises one or more proteins selected from among actin, fibronectin, vitamin-D-binding protein, coagulation factor XIII-A, fibrinogen, complement factor H-associated protein, complement 3, adiponectin, and prothrombin, and can serve as a diagnostic and/or therapeutic marker for idiopathic scoliosis on the basis of the levels of concentration and/or activation of such proteins.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Niimi Hideki
Otsuki Shinya
Kitajima Isao
Abstract
[Problem] To provide an improved melting temperature (Tm) mapping method whereby a microorganism can be accurately discriminated and identified at least at a genus level and mostly at a species level even in the case of using a real-time PCR instrument which shows a Tm value measurement error within ±0.5°C. [Solution] An improved Tm mapping method using imperfect-match long quenching probes whereby a microorganism can be accurately discriminated and identified at least at a genus level and mostly at a species level even in the case of using a real-time PCR instrument which shows a Tm value measurement error within ±0.5°C among PCR tubes. Thus, the Tm mapping method can be carried out with the use of almost all real-time PCR instruments and an unspecified infectious inflammation-causing microorganism can be identified within about 4 hours after collecting a specimen.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
62.
METHOD FOR QUANTIFYING NUMBER OF CELLS OF BACTERIUM IN SAMPLE
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Niimi Hideki
Kitajima Isao
Miyakoshi Akio
Higashi Yoshitsugu
Abstract
The present invention addresses the problem of providing a method whereby it becomes possible to quantify the number of cells of a bacterium in a sample rapidly and with high accuracy by employing PCR method. A method which can solve the problem is a method in which the identification and quantification of bacterial cells in a sample are performed through the following steps: (1) a first PCR step of carrying out PCR method using nucleic acid derived from the sample as a template and also using a universal primer pair for the amplification of 16S rRNA gene in the bacterium to obtain a first amplification product; (2) a second PCR step of carrying out nested PCR method using a primer pair for the amplification of an internal sequence in a sequence occurring in the first amplification product obtained in the first PCR step to produce a second amplification product; and (3) a cell number quantification step of determining the number of cells of the bacterium in the sample from the quantity of the second amplification product obtained in the second PCR step using data for calibration use. In addition to the steps (1) to (3), the following steps (4) and (5) may be additionally carried out: (4) a bacterial species identification step of identifying the species of the bacterium in the sample; and (5) the bacterial cell number correction step of employing the number of cells, which has been obtained in the cell number quantification step, as a provisional number of the cells of the bacterium, and correcting the provisional number of cells on the basis of the number of copies of a 16S rRNA operon of each of the control bacterium and the bacterial species identified in the bacterial species identification step to determine the number of the cells in the sample.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Niimi Hideki
Sugie Kazushige
Kitajima Isao
Ueno Tomohiro
Matsui Atsushi
Abstract
[Problem] To provide a pretreatment method that is capable of minimizing ATP of human origin in a blood sample and that allows an etiologic agent to be directly collected, from the blood sample, while in a viable state. [Solution] A blood sample pretreatment method for ATP assay of an etiologic agent in blood, the method being characterized by comprising a step for pelleting platelets and an etiologic agent from a blood sample, and a step for treating the pelleted platelets and etiologic agent in steps (A)-(C) below in any order, or in two or more of the steps simultaneously. However, for pretreatment of a blood culture sample, the method is characterized by comprising a simplified step in which the following step (A) is not carried out, and only steps (B) and (C) are carried out simultaneously. (A) The platelet membrane protein undergoes protease digestion. (B) The platelets undergo swelling treatment with a hypotonic solution. (C) The platelet membrane is disrupted using a surfactant solution under conditions preventing the etiologic agent from being affected.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Mizutani, Manabu
Yoshida, Katsuhito
Saikawa, Seiji
Abstract
2424222Ca phase. The total area ratio of the group A crystallized matter phases and the group B crystallized matter phases in a cross section is in the range of 2.5-30% inclusive.
C22C 23/02 - Alloys based on magnesium with aluminium as the next major constituent
C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
C22F 1/06 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Tsubota, Maho
Toyooka, Naoki
Nishikawa, Hiroyuki
Abstract
Developed is a novel analgesic, the therapeutic targets of which are T-type calcium channels. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound, or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product which contains this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is T-type calcium channel inhibitory activity. (In the formula, each of R1and R2independently represents H or -OH; R3represents -OH; R4represents -OH or -H; and R5 represents a linear or branched alkyl or cycloalkyl alkyl group having 1-10 carbon atoms, or a linear or branched alkenyl or cycloalkyl alkenyl group having 2-10 carbon atoms.)
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
SHOWA UNIVERSITY (Japan)
Inventor
Kurihara Takashi
Takasaki Ichiro
Toyooka Naoki
Gouda Hiroaki
Abstract
The present invention relates to an analgesic drug containing: a compound represented by formula (I) or (II) (where, R11-61-61-6-haloalkoxy group; R2 is a hydrogen atom; R is an indazolyl group substituted with a halogen atom, a substituted or unsubstituted phenyl group, a pyrazolyl group, or a substituted or unsubstituted aralkyl group.); a salt thereof; or a solvate thereof.
C22C 21/14 - Alloys based on aluminium with copper as the next major constituent with silicon
C22C 21/16 - Alloys based on aluminium with copper as the next major constituent with magnesium
A44B 19/02 - Slide fasteners with a series of separate interlocking members secured to each stringer tape
C22F 1/047 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon of alloys with magnesium as the next major constituent
C22F 1/057 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon of alloys with copper as the next major constituent
C22C 21/08 - Alloys based on aluminium with magnesium as the next major constituent with silicon
C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
68.
HYDROGEN REDUCTION CATALYST FOR CARBON DIOXIDE AND METHOD FOR PRODUCING SAME, HYDROGEN REDUCTION METHOD FOR CARBON DIOXIDE, AND HYDROGEN REDUCTION DEVICE FOR CARBON DIOXIDE
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Shima Asuka
Sone Yoshitsugu
Mendoza Omar
Abe Takayuki
Inoue Mitsuhiro
Abstract
In this hydrogen reduction catalyst for carbon dioxide, catalytic metal nanoparticles and a metal oxide for suppressing grain growth of said catalytic metal nanoparticles, are dispersedly carried on a carrier.
B01J 23/46 - Ruthenium, rhodium, osmium or iridium
B01J 37/02 - Impregnation, coating or precipitation
C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Chiba Junya
Tomohiro Takenori
Hatanaka Yasumaru
Abstract
[Problem] To provide a sulfonyl azide benzoic acid derivative that can be used in a bioorthogonal click reaction. [Solution] The following sulfonyl azide benzoic acid derivative was developed as a compound to be used in a highly versatile bioorthogonal click reaction that advances even in an aqueous solution under mild conditions without need of additives. [In the formula, R1, R2, R3, and R4 are as described in the specification.]
C07C 311/49 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
70.
SUBSTRATE COVERED WITH POLYMERS FOR SELECTIVE SEPARATION OF CELLS OR FOR CELL CULTURING
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
NISSAN CHEMICAL CORPORATION (Japan)
Inventor
Kitano Hiromi
Nakaji Tadashi
Usui Yuki
Nishino Taito
Kishioka Takahiro
Abstract
A liganded substrate having at least part of the surface thereof covered by a polymer (P1) containing a structural unit represented by formula (1a) and (1b), a raw material of said liganded substrate, and a production method thereof are provided. (In the formula, R1,R2, X, Y, L, Q1, Q2, Q3, m1, m2 and n are as set forth in the claims and description.)
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kurosawa, Nobuyuki
Isobe, Masaharu
Abstract
A method for separating cells capable of producing target antigen-specific monoclonal antibodies (TASMAs) wherein a cell group including antibody-producing cells is immobilized using a reversible crosslinking agent having cell membrane-permeating properties. The immobilized cell group is subjected to cell membrane dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen. In the stained cell group a that has reacted with the labeling target antigen is separated. A method to produce TASMAs by separating mRNA from the cell separated using the method; preparing cDNA and preparing antigen-specific monoclonal antibodies or fragments thereof from the prepared cDNA. Also provided are a method whereby at least one cell capable of producing TASMAs is separated and a method whereby said antibodies can be produced by using the separated cell. Threonine 18 phosphorylated p53 (pT18-p53) and threonine 68 phosphorylated CHK2 (pT68-CHK2) specific monoclonal antibodies are also disclosed.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tohda Chihiro
Kaku Taiichi
Miyazaki Hiroyuki
Abstract
Provided is a peptide comprising the amino acid sequence (SEQ ID NO: 1) of GPPGPAG. According to the present invention, a novel compound for treating memory disorder is provided.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
National University Corporation University of Toyama (Japan)
KYOWA KIRIN CO., LTD. (Japan)
Inventor
Ikutani, Masashi
Takatsu, Kiyoshi
Ehara, Hiromi
Fujino, Ikuko
Ogawa, Shinya
Abstract
The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “IL-5R”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tabata, Homare
Minami, Hiroshi
Niimi, Hideki
Kitajima, Isao
Ueno, Tomohiro
Hayashi, Shiroh
Mori, Masashi
Abstract
Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Mizutani, Manabu
Yoshida, Katsuhito
Kawabe, Nozomu
Saikawa, Seiji
Abstract
A magnesium alloy containing 5.0 mass% to 15.0 mass% of Al, 2.5 mass% to 7.0 mass% of Sr, 0.05 mass% to less than 3.0 mass% of Ca, and 0.1 mass% to 0.6 mass% of Mn, the balance being Mg and unavoidable impurities.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Ando Akio
Abstract
An audio signal processing device according to one embodiment is provided with an acceptance unit for accepting audio signals of a plurality of channels, a division unit for dividing the audio signal of each channel into a coherent component and a field component, and an output unit for outputting the coherent component and field component of each channel. In the dividing process, an estimated signal having highest correlation with the audio signal of a channel to be processed among estimated signals calculated using at least the audio signal of other than the channel to be processed, is extracted as the coherent component of the channel to be processed. Then, a difference of the audio signal of the channel to be processed and the coherent component is extracted as a field component.
H04S 7/00 - Indicating arrangementsControl arrangements, e.g. balance control
G10L 19/00 - Speech or audio signal analysis-synthesis techniques for redundancy reduction, e.g. in vocodersCoding or decoding of speech or audio signals, using source filter models or psychoacoustic analysis
77.
DEVICE FOR PRODUCING ETHANOL FROM BIOMASS RESOURCE AND METHOD FOR MANUFACTURING ETHANOL FROM BIOMASS RESOURCE
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tanaka Hiroyuki
Hoshino Kazuhiro
Abstract
[Problem] To provide a technique that enables implementation of a distillation step in which, during saccharification and fermentation, an increase in ethanol concentration in a culture medium is suppressed without transferring impurities such as a raw material or bacterial cells to a distillation device. [Solution] The device for producing ethanol according to the present invention has: a fermentation culture tank for saccharification and fermentation of a biomass resource; a supply outlet that can send a gas to the fermentation culture tank; a recovery tube for liquefying a gas discharged from the fermentation culture tank; and a recovery tank for recovering ethanol discharged from the recovery tube. This device for producing ethanol is used to implement: a fermentation culture step for saccharification and fermentation of a biomass resource; a distillation step for distilling a gas discharged from the fermentation culture tank; and a recovery step for recovering a gas discharged during a gas discharge step.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Sato, Tsutomu
Abstract
The purpose of the present invention is to provide: a medicinal composition for treating plasma cell neoplasm, in particular, multiple myeloma; a method for treating plasma cell neoplasm, said method comprising administering the aforesaid medicinal composition; a method for inducing apoptosis of a myeloma cell, said method comprising bringing a DPP-8 inhibitor into contact with the myeloma cell; etc. The aforesaid purpose has been achieved by a medicinal composition that comprises at least one kind of dipeptidyl peptidase (DPP)-8 activity inhibitor.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSHIMI PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Kato, Atsushi
Ishikawa, Fumihiro
Miura, Daisuke
Abstract
A ceramidase inhibitor which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a ceramide synthesis promoter which comprises a compound represented by formula (II) or a pharmaceutically acceptable salt thereof. The ceramidase inhibitor and ceramide synthesis promoter according to the present invention can increase the amount of ceramide in cells or skin and, therefore, are appropriately usable for, e.g., moisturizing, reducing wrinkles, ameliorating atopic dermatitis symptoms, preventing/treating xeroderma, preventing spots, tightening flabby skin, anti-itching, suppressing melanogenesis, enhancing barrier function, activating fibroblasts and regenerating skin cells.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tsuda Masaaki
Fukuchi Mamoru
Mori Hisashi
Abstract
[Problem] To provide a drug or composition in which the active ingredient is an herbal medicine or extract having BDNF gene expression-inducing activity. [Solution] Licorice, amomum seed, polygonum root, astragalus root, kudzu root, Japanese pepper, red peony root , rhubarb, uncaria hook, sophora, dried aconite tuber, ephedra, Chinese moonseed, and lesser galangal, and extracts thereof, have BDNF gene expression-inducing activity, and a traditional Chinese medicine that uses these herbs alone, mixtures thereof, or these herbs in combination with other herbs is useful in improving the cerebral dysfunction associated with psychiatric disorders and neurodegenerative diseases such as depression and Alzheimer's disease.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Ido,tatewaki
Katsumi,tetsuya
Mikado,koichi
Yoshimura,yasuharu
Matsuda,kenji
Abstract
Provided is an element for slide fasteners, which has improved strength and wear resistance and is made from an aluminum alloy. An element for slide fasteners, which contains, as a matrix, an aluminum alloy having a chemical composition represented by general formula (1): AlaSibCucMgdTieBf (wherein each of a, b, c, d, e and f represents a value of % by mass, and a represents a remainder, 0.2 ≤ b ≤ 0.8, 0.8 ≤ c ≤ 1.8, 0.8 ≤ d ≤ 1.8, 0 < e ≤ 0.05 and 0 < f ≤ 0.01; an unavoidable impurity element may be contained) and having, dispersed therein, precipitates each containing at least one element selected from Al, Si, Cu and Mg, and which is provided with a pair of leg parts and a head part having a raised part and a recessed part both for the joining of the pair of leg parts and for engagement.
C22C 21/06 - Alloys based on aluminium with magnesium as the next major constituent
A44B 19/02 - Slide fasteners with a series of separate interlocking members secured to each stringer tape
C22C 21/12 - Alloys based on aluminium with copper as the next major constituent
C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
C22F 1/047 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon of alloys with magnesium as the next major constituent
C22F 1/057 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon of alloys with copper as the next major constituent
82.
ACTIVATION INHIBITOR FOR TOLL-LIKE RECEPTOR 7 OR TOLL-LIKE RECEPTOR 9
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
TOKYO INSTITUTE OF TECHNOLOGY (Japan)
TEIKA PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Takatsu, Kiyoshi
Nagai, Yoshinori
Okamoto, Naoki
Kobayashi, Yuichi
Fujishita, Shigeto
Abstract
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selectively inhibiting Toll-like receptor 7, or Toll-like receptor 9, and is useful as an active ingredient in an agent for preventing or treating a disease accompanying activation of Toll-like receptor 7, or Toll-like receptor 9.
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
C07C 69/157 - Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
83.
METHOD FOR PRODUCING ANTIGEN-SPECIFIC MONOCLONAL ANTIBODY
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kurosawa Nobuyuki
Isobe Masaharu
Abstract
The present invention relates to a method for separating cells capable of producing target antigen-specific monoclonal antibodies. In said method: a cell group including antibody-producing cells is immobilized using a crosslinking agent (the crosslinking agent is a reversible crosslinking agent having cell membrane-permeating properties); the immobilized cell group is subjected to cell membrance dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen, and in the stained cell group, at least one cell that has reacted with the labeling target antigen is separated. The present invention further relates to a method for producing target antigen-specific monoclonal antibodies. In said method: mRNA is separated from the cell separated using the aforementioned method; cDNA is prepared; and antigen-specific monoclonal antibodies or fragments thereof are prepared from the prepared cDNA. Also provided are a method with which at least one cell capable of producing target antigen-specific monoclonal antibodies can be separated with high accuracy, and a method with which target antigen-specific monoclonal antibodies can be produced by using the cell separated using said method. The present invention further provides new threonine 18 phosphorylated p53 (pT18-p53) specific monoclonal antibodies, and new threonine 68 phosphorylated CHK2 (pT68-CHK2) specific monoclonal antibodies.
B22D 21/00 - Casting non-ferrous metals or metallic compounds so far as their metallurgical properties are of importance for the casting procedureSelection of compositions therefor
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Yakura Takayuki
Andoh Tsugunobu
Nambu Hisanori
Fujiwara Tomoya
Kaneda Hideaki
Abstract
[Problem] To provide a novel therapeutic medicine capable of suppressing the activity of a lipid-metabolizing enzyme deacylase that can cause the decrease in the amount of sphingolipid ceramide in the surface layer of skin, which is one of the causes of the deterioration in a barrier function of skin, to suppress the inflammation of atopic dermatitis and to prevent the recurrence of atopic dermatitis. [Solution] It is assumed that a phytosphingosine derivative having a sulfonyl group has an inhibitory activity on an enzyme (SCDase) which is known to cause the deacylation of sphingomyelin and exhibits an inhibitory activity on sphingomyelin deacylase. Therefore, the phytosphingosine derivative is useful as a therapeutic agent for atopic dermatitis.
C07C 311/17 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
TSS CO., LTD. (Japan)
Inventor
Kajimoto, Hiroyuki
Sato, Michi
Iguchi, Takeyoshi
Asahi, Takashi
Abstract
This orthosis is adjustable to the head size of a user and causes rotary movement of the head. The orthosis 1 is provided with: an outer layer section 2 maintaining an approximately elliptical shape; and a buffer section 3 disposed on the inner circumference of the outer layer section 2 to buffer predetermined portions of the head, wherein pressing sections 24a and 24b are formed which press the predetermined portions of the head 11 more forcefully than before dislocation when the orthosis 1 is worn to be dislocated from a state in which the minor axis in the approximately elliptical shape has a length corresponding to the width of the head. The outer layer section 2 comprises sections 23a and 23b to be adjusted, which approach each other or are separated from each other in the minor axis direction of the approximately elliptical shape. The orthosis 1 is further provided with an adjusting means 4 for adjusting the sections 23a and 23b to be adjusted such that the length of the minor axis of the approximately elliptical shape corresponds to the width of the head.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Andoh Tsugunobu
Kitamura Ryo
Kuraishi Yasushi
Kato Mitsuru
Komatsu Katsuko
Toume Kazufumi
Abstract
[Problem] To provide a medicine useful for the amelioration of paresthesia induced by peripheral nerve disorders. [Solution] An extract from a plant belonging to the genus Plantago (e.g., a Plantago seed, a Plantago herb) is useful for the prevention or treatment of paresthesia, e.g., numbness and pain, induced by peripheral nerve disorders, which is one of adverse side effects of anti-cancer agents.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
SC WORLD, INC. (Japan)
Inventor
Hamana Hiroshi
Kishi Hiroyuki
Muraguchi Atsushi
Shitaoka Kiyomi
Abstract
Provided is a T-cell receptor (TCR) cDNA amplification method that includes steps (1) and (2) below, and is used as a method for amplifying TCR cDNA with high efficiency in a short time. (1) A step for obtaining an amplified product 1 by using at least one L primer described as follows and a C primer 1 or UTR primer 1 described as follows, and performing a PCR using cDNA from one cell as a template: an L primer that has a length of 30-60 bases, and includes an adaptor section having a length of 15-25 bases, and a leader-region association section having a length of 15-25 bases, said leader-region association section being joined downstream of said adaptor section and being associable with a portion of a leader region including a translation initiation codon or upstream thereof; and a C primer 1 that has a length of 15-25 bases and is associable with a portion of a constant region, or a UTR primer 1 that has a length of 15-25 bases and is associable with a portion of a 3' untranslated region. (2) A step for obtaining an amplified product 2 by using an adaptor primer described as follows and a C primer 2 or UTR primer 2 described as follows, and performing a PCR using the amplified product 1 as a template: an adaptor primer that has a length of 15-25 bases and is associable with the adaptor section of the amplified product 1; and a C primer 2 that has a length of 15-25 bases, and is associable with a portion of the constant region upstream of the region where the C primer 1 is associated, or a UTR primer 2 that has a length of 15-25 bases, and is associable with a portion of the 3' untranslated region upstream of the region where the UTR primer 1 is associated.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
TOKYO UNIVERSITY OF SCIENCE FOUNDATION (Japan)
Inventor
Esumi, Hiroyasu
Ikeda, Kouji
Tsuchihara, Katsuya
Chiba, Shigeki
Yomoda, Satoshi
Kawashima Takanori
Okubo, Toshiki
Tezuka, Yasuhiro
Murata, Kenta
Abstract
The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Hiroi, Yoshiomi
Kishioka, Takahiro
Nishino, Taito
Otani, Ayako
Gemmei, Makoto
Abstract
In the present invention, a coating film is formed by a coating-film forming composition being contacted with a base and subsequently being dried. The coating-film forming composition contains a solvent and a copolymer that includes a repeat unit containing an organic group expressed by formula (a) and a repeat unit containing an organic group expressed by formula (b) (in the formula, Ua1 represents a hydrogen atom or an alkali metal atom, and Ub1 and Ub2 each independently represent a hydrogen atom, or a linear or branched alkyl group having 1-5 carbon atoms).
C08F 228/02 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur
C09D 133/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen
C09D 141/00 - Coating compositions based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfurCoating compositions based on derivatives of such polymers
91.
Digital microphone and position-to-frequency converter
National University Corporation University of Toyama (Japan)
Inventor
Maezawa, Koichi
Tanoue, Koichiro
Abstract
A digital microphone includes: a cavity resonator operatable in a micrometer, millimeter, or electromagnetic waveband, the cavity resonator having a metal wall including a conductive membrane 32 that vibrates in response to incident acoustic waves and converts the shift of the membrane 32 into a resonance frequency of the cavity resonator; an FM-signal generator that modulates the resonance frequency of the cavity resonator in response to the shift of the membrane 32 and outputs FM signals from the metal wall other than the membrane; and a ΔΣ-modulated-signal generator that generates ΔΣ-modulated signals from the FM signals. The FM-signal generator includes a slot 36, a micro-strip line 38, and a negative resistive element 40. The ΔΣ-modulated-signal generator includes an edge detector 42.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
TOYAMA PREFECTURE (Japan)
Inventor
Takatsu Kiyoshi
Hirai Yoshikatsu
Nagai Yoshinori
Mathunaga Takayuki
Abstract
[Problem] The present invention addresses the problem of providing an inflammatory cytokine activity inhibitor which is non-invasive and satisfies requirements such as safety, convenience and economic performance, for the purpose of treating diabetes and preventing the development of diabetic complications and as a therapy method for altering the natural history of diabetes, or as an effective means for preventing the progression of diabetes. The present invention also addresses the problem of providing a therapeutic or prophylactic agent for autoinflammatory diseases for which an activity of inhibiting the activity of inflammatory cytokines is effective. [Solution] The inflammatory cytokine activity inhibitor is characterized by containing, as an active ingredient, at least one compound selected from an alkaloid originated from a plant belonging to the family Menispermaceae, the genus Stephania, a derivative of the alkaloid and a pharmaceutically acceptable salt of the alkaloid or the derivative.
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
TOYAMA PREFECTURE (Japan)
Inventor
Nishizono Hirofumi
Yotsushima Kenji
Abstract
[Problem] To provide a technique for improving the conception rate and birth rate in mammals having genetic characteristics such as low conception rate and birth rate in pregnancy by natural mating even though ovulation function and the eggs themselves are seemingly normal; or in ova having lowered conception rate and birth rate due to environment, age, and other such factors. [Solution] To remove the fertilized eggs of a mammal exhibiting low conception rate and low birth rate from the body, culture the eggs in vitro using a medium containing a glycine receptor agonist of a specific concentration, then return the embryos to the mother and bring to term.
C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
AHRESTY CORPORATION (Japan)
Inventor
Saikawa Seiji
Okazawa Gen
Niwa Hiroshige
Terayama Kiyoshi
Ikeno Susumu
Yanagihara Emi
Orii Shin
Takeda Suguru
Abstract
[Problem] To provide an aluminum alloy for cast production and a casting using the same, in which the properties of an Al-Mg-Si aluminum alloy able to obtain high ductility and high strength in an as-cast state of cast production are utilized, and superior cast cracking resistance is exhibited. [Solution] An Al-Mg-Si aluminum alloy characterized in that the Sr content is 0.015-0.12 mass%, and Mg2Si crystallized within a post-cast production metal composition becomes a fine aggregate.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Sasaoka Toshiyashu
Tsuneki Hiroshi
Wada Tsutomu
Toyooka Naoki
Hirono Shuichi
Gota Hiroaki
Abstract
[Problem] To provide a novel drug for improving insulin resistance. [Solution] Benzenesulfonylamino)benzamide derivatives represented by the following general formula (1) (where R1 and R2 are as indicated in the description) or salts thereof have SHIP2 inhibiting action, and are useful as a drug for improving insulin resistance.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
96.
1,5-ANHYDRO-D-GLUCITOL-CONTAINING COLLAGEN PRODUCTION ACCELERATOR
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSHIMI PHARMACEUTICAL CO., LTD. (Japan)
Inventor
Kato, Atsushi
Ishikawa, Fumihiro
Takeshita, Kei
Abstract
A collagen production accelerator, for accelerating production of collagen in cells, containing at least one substance selected from the group consisting of 1,5-anhydro-D-glucitol and derivatives thereof. In addition, a composition containing the collagen production accelerator. This collagen production accelerator containing 1,5-AG or a derivative thereof accelerates production of collagen in cells, and is therefore suitable for use in, e.g., a cosmetic, a medical formulation, or a food item to which the collagen production accelerator is added in order to prevent and/or mitigate skin wrinkling.
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Nikaido Toshio
Koike Chika
Yoshida Toshiko
Okabe Motonori
Abstract
[Problem] To provide a method for selectively and highly amplifying stem cells that are derived from a periplacental tissue, etc. [Solution] A method which comprises primary-culturing and subculturing, at a low cell concentration, a cell mass containing stem cells derived from the placenta, amnion, umbilical cord, etc., in the presence of feeder cells to efficiently prepare stem cells derived from, for example, the placenta, amnion or umbilical cord.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Nita Atsumi
Uno Kyosuke
Abstract
[Problem] To provide: an inspection method for external examination of mental disorders such as drug dependency, schizophrenia, and depression; and an inspection kit used in said inspections. [Solution] An inspection method and an inspection kit for mental disorders, whereby whether or not a human or mouse subject has a mental health disease such as drug dependency, schizophrenia, or depression and the progression of disease pathology can be known by investigating the methylation state of Shati genes of the subject. Accordingly, the present invention is useful for the treatment of mental health disorders such as drug dependency, schizophrenia, and depression and for the development of therapeutic drugs therefor.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Kishi, Hiroyuki
Muraguchi, Atsushi
Abstract
The present invention provides a method of identifying an antigen by directly detecting antigen-presenting cells which have the polynucleotide coding the antigen. An antigen is detected by a method including (1) a step for introducing a reporter structure, which comprises a regulation domain and a polynucleotide that codes a fluorescent protein and is contiguous with the control region on the downstream side thereof, into a cell, said regulation domain being a domain that upregulates the expression of the gene contiguous therewith on the downstream side thereof when the TCR is stimulated by a target antigen, and (2) a step for introducing a polynucleotide that codes an antigen candidate into the cell, said antigen candidate being expressed within the cell and binding with major histocompatibility complex (MHC) molecules so that a portion or the entirety of the antigen candidate is presented on the cell surface, wherein cells that emit fluorescent light from the fluorescent proteins are selected as cells into which the polynucleotide that codes the target antigen has been introduced.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
Inventor
Tsubaki Noritatsu
Ishiyama Takeshi
Shibata Yusuke
Higashimura Hideyuki
Yuasa Akihiro
Abstract
A method for producing an olefin having 2-4 carbon atoms, which comprises a step wherein at least one catalyst (D) that is selected from the group consisting of the catalysts (A)-(C) described below is reacted with a synthetic gas in the coexistence of a dispersion medium in a Fischer-Tropsch reaction. The catalyst (A) is a catalyst that contains iron and one to three elements that are selected from the group consisting of alkali metals and alkaline earth metals. The catalyst (B) is a catalyst that contains cobalt, provided that the catalyst (B) is a catalyst other than catalysts which are obtained by reducing cobalt ions and iron ions in a dispersion liquid or a solution that contains cobalt ions, iron ions and a dispersant which is interactive with the cobalt ions and the iron ions. The catalyst (C) is a catalyst that contains nickel or ruthenium.
C07C 1/04 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon monoxide with hydrogen
patents
